Clinical Trial Update: FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) [Phase 3]

View source ↗

Summary

A Phase 3 trial of SGX301 (synthetic hypericin) topical treatment for cutaneous T-cell lymphoma (mycosis fungoides) has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides

Drugs mentioned

• SGX301 (synthetic hypericin)

Snippet

Sponsor: Soligenix | Conditions: Cutaneous T-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2022-04-15